Naringenin pretreatment attenuates hepatic ischemia-reperfusion injury by activating the PI3K-Akt signaling pathway

Figure 6 Naringenin attenuates hepatic ischemia-reperfusion injury through activation of the phosphatidylinositol 3-kinase-protein kinase B signaling pathway. A: Serum levels of alanine aminotransferase (n = 6); B: Serum levels of aspartate aminotransferase (n = 6); C: Suzuki pathological scores of liver injury based on hematoxylin and eosin staining (n = 6); D: Hematoxylin and eosin staining of liver sections; E: In vitro western blots showing protein expression levels of p-phosphatidylinositol 3-kinase (PI3K), p-protein kinase B (Akt), Bax and Bcl-2; F: Densitometric quantification of p-PI3K, p-Akt, Bax and Bcl-2 (n = 3); G: In vivo western blots showing protein expression levels of p-PI3K, p-Akt, Bax and Bcl-2; H: Densitometric quantification of p-PI3K, p-Akt, Bax and Bcl-2 (n = 3). Scale bar: 100 μm. ^aP < 0.05 vs the ischemia-reperfusion injury group, ^bP < 0.05 vs the ischemia-reperfusion injury + naringenin group. NAR: Naringenin; IRI: Ischemia-reperfusion injury; PI3K: Phosphatidylinositol 3-kinase; Akt: Protein kinase B; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.